Simultaneous evaluation of substrate‐dependent CYP3A inhibition using a CYP3A probe substrates cocktail. (September 2016)
- Record Type:
- Journal Article
- Title:
- Simultaneous evaluation of substrate‐dependent CYP3A inhibition using a CYP3A probe substrates cocktail. (September 2016)
- Main Title:
- Simultaneous evaluation of substrate‐dependent CYP3A inhibition using a CYP3A probe substrates cocktail
- Authors:
- Lee, Eunyoung
Shon, Jong Cheol
Liu, Kwang‐Hyeon - Abstract:
- Abstract: Cytochrome P450 (P450) 3A (CYP3A) is an enzyme responsible for the metabolism of therapeutic drugs such as midazolam, nifedipine, testosterone and triazolam. It is involved in 40% of all cases of P450‐mediated metabolism of marketed drugs. Therefore, it is important to evaluate the CYP3A‐mediated drug interaction potential of new chemical entities (NCEs). In the past, one P450 isoform‐specific probe substrate has been used at a time to evaluate the degree of inhibition of P450 isoforms by using liquid chromatography‐tandem mass spectrometry (LC‐MS/MS). However, CYP3A enzymes have been shown to have a multi‐substrate binding site. Therefore, multiple CYP3A substrates should be used to evaluate precisely the drug interaction potential of NCEs with the enzyme CYP3A. In this study, a method of screening NCEs for their potential to inhibit by CYP3A enzyme activity was developed. It involves the employment of a CYP3A substrate cocktail (including midazolam, testosterone and nifedipine). The concentration of each CYP3A probe substrate in vitro was optimized (0.1 μm for midazolam, 2 μm for testosterone and 2 μm for nifedipine) to minimize mutual drug interactions among probe substrates. The method was validated by comparing inhibition data obtained from the incubation of CYP3A with each individual substrate with data from incubation with a cocktail of all three substrates. The CYP3A inhibition profiles from the substrate cocktail approach were similar to those from theAbstract: Cytochrome P450 (P450) 3A (CYP3A) is an enzyme responsible for the metabolism of therapeutic drugs such as midazolam, nifedipine, testosterone and triazolam. It is involved in 40% of all cases of P450‐mediated metabolism of marketed drugs. Therefore, it is important to evaluate the CYP3A‐mediated drug interaction potential of new chemical entities (NCEs). In the past, one P450 isoform‐specific probe substrate has been used at a time to evaluate the degree of inhibition of P450 isoforms by using liquid chromatography‐tandem mass spectrometry (LC‐MS/MS). However, CYP3A enzymes have been shown to have a multi‐substrate binding site. Therefore, multiple CYP3A substrates should be used to evaluate precisely the drug interaction potential of NCEs with the enzyme CYP3A. In this study, a method of screening NCEs for their potential to inhibit by CYP3A enzyme activity was developed. It involves the employment of a CYP3A substrate cocktail (including midazolam, testosterone and nifedipine). The concentration of each CYP3A probe substrate in vitro was optimized (0.1 μm for midazolam, 2 μm for testosterone and 2 μm for nifedipine) to minimize mutual drug interactions among probe substrates. The method was validated by comparing inhibition data obtained from the incubation of CYP3A with each individual substrate with data from incubation with a cocktail of all three substrates. The CYP3A inhibition profiles from the substrate cocktail approach were similar to those from the individual substrates approach. This new method could be an effective tool for the robust and accurate screening of the CYP3A inhibition potential of NCEs in drug discovery. Copyright © 2016 John Wiley & Sons, Ltd. … (more)
- Is Part Of:
- Biopharmaceutics & drug disposition. Volume 37:Number 6(2016:Sep.)
- Journal:
- Biopharmaceutics & drug disposition
- Issue:
- Volume 37:Number 6(2016:Sep.)
- Issue Display:
- Volume 37, Issue 6 (2016)
- Year:
- 2016
- Volume:
- 37
- Issue:
- 6
- Issue Sort Value:
- 2016-0037-0006-0000
- Page Start:
- 366
- Page End:
- 372
- Publication Date:
- 2016-09
- Subjects:
- cytochrome P450 -- drug–drug interactions -- mass spectrometry/MS
Biopharmaceutics -- Periodicals
Drugs -- Metabolism -- Periodicals
Pharmacology -- Periodicals
Biopharmaceutics -- Periodicals
Pharmaceutical Preparations -- metabolism -- Periodicals
615.19 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1002/bdd.2019 ↗
- Languages:
- English
- ISSNs:
- 0142-2782
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2089.355000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 2481.xml